As GLP-1 medications such as Ozempic, Mounjaro and Wegovy rise in popularity, so do concerns over their side effects.

Utah’s Attorney General Derek Brown signed onto a letter along with attorneys general from 37 other states to ask the Food and Drug Administration to enforce the safety of weight loss drugs.

Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

Semaglutide injections, which have become a popular treatment option for weight loss as well as Type 2 diabetes, have been ...

Discover how this diabetes drug is revolutionizing heart health. Learn about its surprising benefits in reducing cardiovascular risks and mortality.

Shares of Hims & Hers Health ( HIMS -24.30%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...

The FDA has determined that the nationwide shortage of semaglutide injection, used for both diabetes and weight loss, is resolved after more than two years of limited availability due to high demand.

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.